Structure | Compound Name | Standard Type | Standard Values (in nM) |
|---|---|---|---|
| Imatinib | IC50 | 30000.0 [1], 100000.0 [2] | |
| Bosutinib | IC50 | 150.0 [1], 200.0 [2], 10000.0 [3], 20000.0 [4] | |
| 6-(2,6-Dichlorophenyl)-8-methyl-2-((3-(methylthio)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one | IC50 | 2500.0 [1], 3000.0 [2], 30000.0 [3] | |
| N-[2-[2-[4-[4-[(2S)-2-Hydroxypropyl]piperazin-1-yl]-2-methoxyanilino]pyrrolo[2,1-f][1,2,4]triazin-7-yl]phenyl]-N-methylmethanesulfonamide | IC50 | 60.0 [1] | |
| 5-(1,3-Benzodioxol-5-yl)-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxo-1H-pyridine-3-carboxamide | IC50 | 3600.0 [1], 6500.0 [2] | |
MLA | "Quest Database™ NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) Inhibitors (IC50, Ki)." AAT Bioquest, Inc., 14 Dec. 2025, https://www.aatbio.com/data-sets/npm-alk-nucleophosmin-alk-tyrosine-kinase-receptor-inhibitors-ic50-ki. | |
APA | AAT Bioquest, Inc. (2025, December 14). Quest Database™ NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) Inhibitors (IC50, Ki). AAT Bioquest. https://www.aatbio.com/data-sets/npm-alk-nucleophosmin-alk-tyrosine-kinase-receptor-inhibitors-ic50-ki. | |
| BibTeX | EndNote | RefMan |